Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
David Dalvey sold 109,325 shares of CELC on 28 July at $46.05 per share, worth a total of $5.0M. They now own 167,956 CELC shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
